Taku Okazaki

发表

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

T. Okazaki, T. Honjo, M. Muramatsu, 2011, The Journal of experimental medicine.

The PD-1-PD-L pathway in immunological tolerance.

T. Okazaki, T. Honjo, Taku Okazaki, 2006, Trends in immunology.

PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

T. Okazaki, T. Honjo, Yoshiko Iwai, 2003, The Journal of experimental medicine.

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

G. Freeman, M. Byrne, T. Okazaki, 2000, The Journal of experimental medicine.

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

G. Freeman, T. Okazaki, T. Honjo, 2001, Nature Immunology.

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

T. Okazaki, T. Honjo, N. Minato, 2001, Science.

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4

T. Okazaki, T. Honjo, K. McCoy, 2005, Nature Immunology.

Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade

T. Okazaki, T. Katakai, Y. Kanda, 2021, Cancers.

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

T. Okazaki, T. Honjo, K. Kabashima, 2010, Cancer.

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Yoshimasa Tanaka, Masashi Iwasaki, T. Okazaki, 2007, Proceedings of the National Academy of Sciences.

PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation.

T. Okazaki, I. Okazaki, D. Sugiura, 2019, Molecular cell.

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Yoshimasa Tanaka, T. Okazaki, T. Honjo, 2002, Proceedings of the National Academy of Sciences of the United States of America.

LAG-3: from molecular functions to clinical applications

T. Okazaki, I. Okazaki, D. Sugiura, 2020, Journal for ImmunoTherapy of Cancer.

PD-1 and PD-1 ligands: from discovery to clinical application.

T. Okazaki, T. Honjo, Taku Okazaki, 2007, International immunology.

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

T. Okazaki, T. Honjo, S. Fagarasan, 2013, Nature Immunology.

PD-1 preferentially inhibits the activation of low-affinity T cells

T. Okazaki, I. Okazaki, D. Sugiura, 2021, Proceedings of the National Academy of Sciences.

Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE).

T. Okazaki, K. Mitsumori, M. Matsumoto, 2018, Journal of autoimmunity.

Robotic data acquisition with deep learning enables cell image–based prediction of transcriptomic phenotypes

T. Ikawa, T. Imanishi, K. Shiroguchi, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.

T. Okazaki, N. Ishimaru, I. Okazaki, 2022, Immunity.

Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.

Yoshimasa Tanaka, B. Mikami, T. Okazaki, 2007, International immunology.

The PD-1 / PD-L 1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

D. Y. Lin, Yoshimasa Tanaka, Masashi Iwasaki, 2008 .

Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

G. Freeman, Yoshimasa Tanaka, T. Okazaki, 2002, Immunology letters.

Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.

T. Okazaki, T. Honjo, Taku Yoshida, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

Yoshimasa Tanaka, T. Okazaki, T. Honjo, 2003, Nature Medicine.

Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation

T. Okazaki, I. Okazaki, D. Sugiura, 2019, The Journal of Biological Chemistry.

Inhibitory mechanisms of LAG-3-dependent T cell suppression Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation

T. Okazaki, I. Okazaki, D. Sugiura, 2019 .

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

D. Y. Lin, Yoshimasa Tanaka, Masashi Iwasaki, 2008, Proceedings of the National Academy of Sciences.

IFN-γ is reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach

T. Okazaki, T. Chiba, N. Watanabe, 2012, Autoimmunity.

Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling.

T. Okazaki, T. Honjo, T. Chiba, 2008, Gastroenterology.

IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

T. Okazaki, T. Honjo, Tamon Hayashi, 2011, The Journal of Immunology.

Stimulatory and Inhibitory Co-signals in Autoimmunity.

T. Okazaki, I. Okazaki, Taku Okazaki, 2019, Advances in experimental medicine and biology.

New regulatory co-receptors: inducible co-stimulator and PD-1.

T. Okazaki, T. Honjo, Yoshiko Iwai, 2002, Current opinion in immunology.

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

T. Okazaki, I. Okazaki, D. Sugiura, 2018, Nature Immunology.

PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation

T. Okazaki, I. Okazaki, D. Sugiura, 2019, Front. Immunol..

T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.

H. Aburatani, T. Okazaki, T. Honjo, 2009, Investigative ophthalmology & visual science.

Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy.

T. Okazaki, T. Honjo, Taku Okazaki, 2005, Trends in molecular medicine.

PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice

T. Okazaki, T. Honjo, Taku Yoshida, 2008, Proceedings of the National Academy of Sciences.

RBP-L, a transcription factor related to RBP-Jkappa

S. Minoguchi, T. Honjo, Y. Taniguchi, 1997, Molecular and cellular biology.

RBP-L, a Transcription Factor Related to RBP-J k

S. Minoguchi, T. Okazaki, T. Honjo, 1997 .

PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

T. Okazaki, T. Kurosaki, A. Maeda, 2001, Proceedings of the National Academy of Sciences of the United States of America.

A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium.

T. Okazaki, E. Ogata, S. Ebisu, 1994, The Journal of biological chemistry.

Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.

T. Komori, S. Maeda, Yoshimasa Tanaka, 2005, The Journal of rheumatology.

Microanatomical localization of PD-1 in human tonsils.

T. Okazaki, T. Honjo, Yoshiko Iwai, 2002, Immunology letters.

PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guérin.

T. Okazaki, I. Kawamura, M. Mitsuyama, 2010, International immunology.

Duration of T Cell-Mediated Immunity Death-1 Transcription and Limits the Directly Promotes Programmed Cell a IFN-HonjoTamon

T. Okazaki, Tamon Hayashi, S. Chikuma, 2011 .

Anti-Programmed Cell Death 1 Antibody Reduces CD4+PD-1+ T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice

Tasuku Honjo, Nagahiro Minato, Seiji Kawano, 2010, The Journal of Immunology.

PD-1 deficiency results in the development of fatal myocarditis in MRL mice.

T. Okazaki, T. Honjo, I. Okazaki, 2010, International immunology.

Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs

T. Naoe, T. Ochiya, Y. Sugiyama, 2016, Cancer science.

Title Report on the use of non-clinical studies in the regulatoryevaluation of oncology drugs

T. Naoe, T. Ochiya, Y. Sugiyama, 2019 .

Role of PD-1 in regulating T-cell immunity.

T. Okazaki, R. Ahmed, H. Jin, 2011, Current topics in microbiology and immunology.

Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice.

T. Okazaki, T. Honjo, I. Okazaki, 2009, International immunology.

Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis

M. Ishii, Masahiro Yamamoto, T. Okazaki, 2012, Proceedings of the National Academy of Sciences.

TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression.

T. Okazaki, T. Chiba, N. Watanabe, 2013, Clinical immunology.

PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo1

T. Okazaki, T. Honjo, Tamon Hayashi, 2009, The Journal of Immunology.

DCIR acts as an inhibitory receptor depending on its immunoreceptor tyrosine-based inhibitory motif.

T. Okazaki, K. Tashiro, H. Nishimura, 2002, The Journal of investigative dermatology.

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

T. Okazaki, I. Okazaki, D. Sugiura, 2019, Science.

Single-cell level temporal profiling of tumour-reactive T cells under immune checkpoint blockade

T. Okazaki, I. Okazaki, B. J. Tan, 2022, bioRxiv.

This information is current as the Lupus-Like Nephritis of NZB / W F 1 Mice T Cells and Relieves + PD-1 + Reduces CD 4 Anti-Programmed Cell Death 1 Antibody

T. Okazaki, T. Honjo, N. Minato, 2010 .

Anti–PD-1 Antibody Reduces CD4PD-1 T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice

T. Okazaki, T. Honjo, N. Minato, 2010 .

PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity

T. Okazaki, N. Ishimaru, I. Okazaki, 2022, Nature Immunology.

Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells

T. Okazaki, I. Okazaki, D. Sugiura, 2019, The Journal of Biological Chemistry.

PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions.

T. Okazaki, I. Okazaki, D. Sugiura, 2019, Journal of autoimmunity.

Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis

M. Ishii, Masahiro Yamamoto, K. Takeda, 2012, Proceedings of the National Academy of Sciences.

PD-1/PD-L pathway and autoimmunity

T. Okazaki, Jian Wang, Taku Okazaki, 2005, Autoimmunity.

Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice.

Yoshimasa Tanaka, T. Chiba, N. Watanabe, 2011, Gastroenterology.

Anti-Programmed Cell Death 1 Antibody Reduces CD4+PD-1+ T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice

Yoshimasa Tanaka, T. Honjo, N. Minato, 2010, The Journal of Immunology.

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

T. Honjo, K. Kabashima, Y. Tokura, 2010, Cancer.

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

I. Okazaki, D. Sugiura, K. Shimizu, 2018, Nature Immunology.

The Programmed Death-1 and Interleukin-10 Pathways Play a Down-Modulatory Role in LP-BM5 Retrovirus-Induced Murine Immunodeficiency Syndrome

T. Okazaki, T. Honjo, W. Cook, 2007, Journal of Virology.

Rejuvenating Exhausted T Cells during Chronic Viral Infection

T. Okazaki, T. Honjo, Taku Okazaki, 2006, Cell.

Vivo T Cell Anergy In + Production Induces CD 8 PD-1-Mediated Suppression of IL-2 Taku Okazaki and Tasuku Honjo

T. Honjo, Tamon Hayashi, S. Chikuma, 2009 .

Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b −/− Pdcd1 −/− mice

T. Honjo, J. Ravetch, T. Takai, 2005, The Journal of experimental medicine.